Catalent Pharma Solutions has entered into a contract with Biota Pharmaceuticals, Inc. to provide filling and packaging of clinical trial materials of laninamivir octanoate, an inhaled long-acting neuraminidase inhibitor in development for the treatment of influenza A and B viruses.
In 2012, Catalent began working on the inhalation formulation feasibility studies, device filling, and analytical support from its facilities in Research Triangle Park (RTP), NC. Catalent will provide clinical packaging services from its Clinical Supply Services facility in Philadelphia, PA for Biota’s dry powder inhaler, which is used to administer laninamivir octanoate.
Scott Houlton, president of Catalent’s Development and Clinical Services business, said, “We continue to invest extensively at our Inhalation Center of Excellence in order to fulfill our customers’ increasing demands in this expanding drug delivery market. Our work with Biota on the development of laninamivir octanoate is an illustration of how we work with our clients to meet their inhaled product development needs.”